Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide.
Slightly overvalued with limited growth.
Share Price & News
How has Sorrento Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 8STN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 8STN exceeded the German Biotechs industry which returned 8.4% over the past year.
Return vs Market: 8STN exceeded the German Market which returned 13.7% over the past year.
Price Volatility Vs. Market
How volatile is Sorrento Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Sorrento Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 8STN (€2.4) is trading below our estimate of fair value (€3.67)
Significantly Below Fair Value: 8STN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 8STN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 8STN is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 8STN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 8STN is overvalued based on its PB Ratio (7.1x) compared to the DE Biotechs industry average (3.5x).
How is Sorrento Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8STN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 8STN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 8STN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 8STN's revenue (39.3% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: 8STN's revenue (39.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 8STN's Return on Equity is forecast to be high in 3 years time
How has Sorrento Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 8STN is currently unprofitable.
Growing Profit Margin: 8STN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 8STN is unprofitable, and losses have increased over the past 5 years at a rate of -44.7% per year.
Accelerating Growth: Unable to compare 8STN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8STN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 8STN has a negative Return on Equity (-5207.72%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Sorrento Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: 8STN's short term assets ($67.6M) do not cover its short term liabilities ($112.7M).
Long Term Liabilities: 8STN's short term assets ($67.6M) do not cover its long term liabilities ($441.5M).
Debt to Equity History and Analysis
Debt Level: 8STN's debt to equity ratio (3902.3%) is considered high.
Reducing Debt: 8STN's debt to equity ratio has increased from 16.9% to 3902.3% over the past 5 years.
Inventory Level: 8STN has a low level of unsold assets or inventory.
Debt Coverage by Assets: 8STN's debt is not covered by short term assets (assets are 0.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 8STN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 8STN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -35.7% each year
What is Sorrento Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 8STN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 8STN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 8STN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 8STN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 8STN's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Henry Ji (55yo)
Dr. Henry H. Ji, Ph.D. co-founded Sorrento Therapeutics, Inc. (STI) in January 2006 and has been its Chief Executive Officer and President since September 2012 and also has been its Chairman since August 1 ...
CEO Compensation Analysis
Compensation vs Market: Henry's total compensation ($USD4.50M) is above average for companies of similar size in the German market ($USD792.68K).
Compensation vs Earnings: Henry's compensation has increased whilst the company is unprofitable.
|Executive VP & CFO||1.9yrs||US$3.44m||no data|
|Chief Medical Officer & President of Clinical Development||3.5yrs||US$638.22k||0.0062% $24.2k|
|Senior Vice President & General Counsel||2.1yrs||no data||no data|
|Senior Vice President of Corporate Development||2.4yrs||no data||no data|
|Vice President of Sales & Business Development||2.4yrs||no data||no data|
Experienced Management: 8STN's management team is considered experienced (2.4 years average tenure).
|Independent Director||2.4yrs||US$161.43k||no data|
|Director||0.2yrs||no data||0.012% $48.4k|
|Independent Director||6.4yrs||US$178.00k||0.070% $272.4k|
|Chairman of Scientific Advisory Board||0yrs||no data||0.13% $511.7k|
|Lead Independent Director||0.9yrs||US$180.68k||0.0019% $7.2k|
|Director||0.2yrs||no data||no data|
|Independent Director||3.5yrs||US$178.55k||0.0031% $12.1k|
|Independent Director||2.4yrs||US$158.80k||0.0013% $5.2k|
Experienced Board: 8STN's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.7%.
Sorrento Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Sorrento Therapeutics, Inc.
- Ticker: 8STN
- Exchange: DB
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$418.200m
- Listing Market Cap: US$387.504m
- Shares outstanding: 160.23m
- Website: https://www.sorrentotherapeutics.com
Number of Employees
- Sorrento Therapeutics, Inc.
- 4955 Directors Place
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SRNE||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Sep 2009|
|8STN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2009|
|0L85||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Sep 2009|
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It also develops CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. The company has a cooperation framework agreement with LifeTech Scientific Corporation for the research and development, production, and commercialization of water-soluble cannabidiol and other water-soluble cannabinoids products; and clinical and manufacturing collaboration with Celularity, Inc. to initiate emergency allogeneic natural killer cell therapy development for coronavirus infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 22:19|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.